Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
about
Pharmacology of iron transportPharmacogenetic study of deferasirox, an iron chelating agentTailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosisLong-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia.Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective studyDeferiprone in the treatment of transfusion-dependent thalassemia: a review and perspectiveBody iron metabolism and pathophysiology of iron overload.Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.Korean guideline for iron chelation therapy in transfusion-induced iron overload.Deferasirox pharmacokinetics in patients with adequate versus inadequate response.Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.Early detection of cardiac involvement in thalassemia: From bench to bedside perspective.Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.Efficacy and Safety of Deferasirox in Pediatric Patients of Thalassemia at a Tertiary Care Teaching HospitalRecent advances in β-thalassemiasSafety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five years' experience of chelation treatment.Update on the use of deferasirox in the management of iron overload.Ocular findings in children with thalassemia major in Eastern Mediterranean.Iron chelation therapy in thalassemia syndromesInterventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemiaDeferasirox: Over a Decade of Experience in Thalassemia
P2860
Q27009387-060E9266-AF44-47C2-9D7F-33CA4B2B5D6AQ28533457-53888337-5DDB-49F1-BBAC-4B272627AB67Q33801826-9DC07195-7D8B-4BF1-9FF3-DBA10AD44996Q34553682-37CB4658-6560-4DB4-931B-90CD810CFAD0Q35206809-CC245AA9-B063-436D-8CE2-E97849415D7CQ35589778-D49FBC4F-C118-4123-B651-21782081F527Q35683841-87F8BE92-4673-4119-B0C3-22DAEC7EB137Q35919222-5547AD0B-E53D-4139-8114-5F6D39ED85C8Q36158835-3F32B555-6E01-43F8-8E9B-A0FCF3941EEAQ36499650-1FD6F1A6-377C-4189-BFD2-8F96D4049679Q36645815-D1D58919-27D2-4812-9516-CCE8DA7A00EBQ37205002-D0C929EE-5368-49E2-8231-B36D155F3493Q37314847-EC3B0FB5-424E-4748-9F29-0620A5634E5CQ37329555-13A2621D-307B-4E79-BB30-1A457C77C8C8Q37414682-C7A58390-3238-4B0A-9FD8-3F5D7CF4E9C3Q37427326-FCA444ED-4B0C-46F9-97CF-59C274390498Q38134738-EF9B8AA4-301C-4CE6-894C-8E0FD4B79DDCQ38540491-78587539-A9CF-423C-880D-5002CADFBCC4Q41601748-3EEB26E2-B5F8-4E47-8937-59B64A59644AQ41973193-0121321D-3ADE-4E2E-9469-163F55C44256Q42013707-43B434B5-80B7-4A9E-92C9-8C8165F52BE6Q42117340-C560F4F2-87B0-481A-A512-4A35B1665772Q42414480-661AD05F-B95B-4252-9B90-CF768EF7BA90Q42588949-2D7E5C58-354D-4B90-97F1-72915B14BFEBQ56389520-39566269-30AE-4AFD-97E4-0B65C41DF6F4Q58701123-45051AA8-8477-457D-878C-3B7F06D5AC43
P2860
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@ast
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@en
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@nl
type
label
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@ast
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@en
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@nl
prefLabel
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@ast
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@en
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@nl
P2093
P1433
P1476
Phase II clinical evaluation o ...... s with beta-thalassemia major.
@en
P2093
Antonella Lavagetto
Antonietta Zappu
Antonio Piga
Daniele Alberti
Elena Bordone
Filomena Longo
Gian Luca Forni
Giovanbattista Leoni
Henry Maseruka
Maria Loreta Foschini
P304
P577
2006-10-01T00:00:00Z